JACOBS LEVY EQUITY MANAGEMENT, INC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$9,531,519
-23.1%
861,801
-6.7%
0.06%
-27.6%
Q1 2023$12,400,846
+8.6%
923,369
+0.0%
0.08%
-1.3%
Q4 2022$11,418,834
+4.8%
923,107
+18.2%
0.08%
-10.5%
Q3 2022$10,894,000
+22.2%
780,945
+20.9%
0.09%
+24.6%
Q2 2022$8,917,000
-7.5%
645,691
+9.0%
0.07%
+6.2%
Q1 2022$9,637,000
+0.4%
592,304
+0.6%
0.06%
+1.6%
Q4 2021$9,594,000
+20.9%
588,922
+10.2%
0.06%
+20.8%
Q3 2021$7,933,000
-35.3%
534,176
-13.0%
0.05%
-36.1%
Q2 2021$12,259,000
-0.2%
613,888
+15.4%
0.08%
-12.6%
Q1 2021$12,281,000
+3.6%
532,102
+10.9%
0.10%
-8.7%
Q4 2020$11,849,000
-17.7%
479,724
+38.2%
0.10%
-30.2%
Q3 2020$14,397,000
+507.7%
347,246
+602.1%
0.15%
+473.1%
Q2 2020$2,369,000
-14.5%
49,457
+12.4%
0.03%
-27.8%
Q1 2020$2,770,000
-49.6%
44,002
-0.8%
0.04%
-33.3%
Q4 2019$5,495,000
+105.5%
44,342
+10.1%
0.05%
+63.6%
Q3 2019$2,674,000
+130.7%
40,292
+396.2%
0.03%
+37.5%
Q2 2016$1,159,000
-30.8%
8,120
-37.7%
0.02%
-31.4%
Q1 2016$1,675,00013,0400.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders